Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma of Lung 1

Interventions

Paclitaxel 6Carboplatin 6Radiotherapy 5Erlotinib Hydrochloride 4pembrolizumab 3aldesleukin 2Nivolumab 2Magnetic Resonance Spectroscopy 2Interleukin-2 2Cyclophosphamide 2Bevacizumab 2veliparib 1trametinib 1spartalizumab 1satraplatin 1osimertinib 1onartuzumab 1nintedanib 1methyl-4-fluoro-4-deoxyglucose 1fludarabine phosphate 1fludarabine 1bemarituzumab 1anlotinib 1aflutinib 1Taxes 1Sorafenib 1Sirolimus 1Radiotherapy, Conformal 1Radiosurgery 1Pentostatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Adenocarcinoma of Lung × onartuzumab × Clear all
NCT02044601 2014-04-24

Biomarker-Integrated Approach of Targeted Therapy for Lung Cancer Elimination Plus External Beam Radiation Therapy (BATTLE-XRT)

M.D. Anderson Cancer Center

Phase 1/2 Withdrawn
Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡